G. Schreibelt

发表

CD 1 and Major Histocompatibility Complex II Molecules Follow a Different Course during Dendritic Cell Maturation

P. Peters, N. V. D. Wel, M. Brenner, 2003 .

PLGA-encapsulated perfluorocarbon nanoparticles for simultaneous visualization of distinct cell populations by 19F MRI.

C. Figdor, A. Heerschap, J. Tel, 2015, Nanomedicine.

The C-type lectin receptor CLEC9A mediates antigen uptake and (cross-)presentation by human blood BDCA3+ myeloid dendritic cells.

C. Figdor, G. Adema, J. Tel, 2012, Blood.

Oxidative Stress in Multiple Sclerosis Pathology and Therapeutic Potential of Nrf2 Activation

H. D. Vries, J. Horssen, G. Schreibelt, 2011 .

Blood-Brain Barrier Integrity the Central Nervous System and Stabilizes Lipoic Acid Affects Cellular Migration into

R. Musters, C. Dijkstra, A. Reijerkerk, 2013 .

Blood-Brain Barrier Integrity the Central Nervous System and Stabilizes Lipoic Acid Affects Cellular Migration into Drukarch and

R. Musters, C. Dijkstra, A. Reijerkerk, 2006 .

Lipoic Acid Affects Cellular Migration into the Central Nervous System and Stabilizes Blood-Brain Barrier Integrity1

R. Musters, H. D. de Vries, Esther M L Hendrikx, 2006, The Journal of Immunology.

Enterovirus-Infected β-Cells Induce Distinct Response Patterns in BDCA1+ and BDCA3+ Human Dendritic Cells

G. Adema, F. V. van Kuppeveld, B. Schulte, 2015, PloS one.

Commonly used prophylactic vaccines as an alternative for synthetically produced TLR ligands to mature monocyte-derived dendritic cells.

C. Figdor, C. Punt, G. Adema, 2010, Blood.

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients

C. Figdor, C. Punt, B. Neyns, 2015, Oncoimmunology.

Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells

C. Figdor, C. Punt, G. Adema, 2009, Cancer Immunology, Immunotherapy.

BDCA1+CD14+ Immunosuppressive Cells in Cancer, a Potential Target?

E. Smits, V. V. Van Tendeloo, I. D. de Vries, 2018, Vaccines.

Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines.

C. Figdor, C. Schröder, S. P. Sittig, 2016, Cancer research.

Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients

W. Oyen, C. Figdor, C. Punt, 2011, Clinical Cancer Research.

5 Therapeutic potential and biological role of antioxidants and antioxidant enzymes in multiple sclerosis pathology

B. Drukarch, C. Dijkstra, J. Horssen, 2012 .

Therapeutic potential and biological role of endogenous antioxidant enzymes in multiple sclerosis pathology

H. D. Vries, B. Drukarch, C. Dijkstra, 2007, Brain Research Reviews.

4 Reactive oxygen species induce adaptive responses in brain endothelial cells through peroxiredoxin 1

I. Blasig, E. Ronken, E. Krause, 2012 .

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity

W. Oyen, C. Figdor, C. Punt, 2016, Cancer Immunology, Immunotherapy.

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets

C. Figdor, S. P. Sittig, J. Tel, 2016, Mediators of inflammation.

Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells

S. P. Sittig, F. Wimmers, I. D. de Vries, 2018, Cancer Immunology and Immunotherapy.

Human pDCs Are Superior to cDC2s in Attracting Cytolytic Lymphocytes in Melanoma Patients Receiving DC Vaccination.

J. Textor, K. Bol, I. D. de Vries, 2020, Cell reports.

Novel Concepts in Dendritic Cell Vaccination against Cancer

C. Figdor, I. J. Vries, G. Schreibelt, 2012 .

Immunological responses to adjuvant vaccination with combined CD1c+ myeloid and plasmacytoid dendritic cells in stage III melanoma patients

C. Figdor, R. Koornstra, S. Croockewit, 2021, Oncoimmunology.

Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells

C. Figdor, C. Punt, C. Blank, 2015, Clinical Cancer Research.

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer

B. Neyns, Z. Berneman, J. Borst, 2022, Oncoimmunology.

Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy

C. Figdor, F. Wimmers, I. D. de Vries, 2014, Oncoimmunology.

Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets

S. P. Sittig, J. Tel, I. D. de Vries, 2015, Cancer Immunology, Immunotherapy.

Dendritic cell vaccination in melanoma patients: From promising results to future perspectives

W. Gerritsen, I. D. de Vries, M. Bloemendal, 2016, Human vaccines & immunotherapeutics.

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients

C. Figdor, C. Punt, J. D. de Wilt, 2016, Oncoimmunology.

Protective effects of peroxiredoxin-1 at the injured blood-brain barrier.

I. Blasig, H. D. de Vries, E. Ronken, 2008, Free radical biology & medicine.

Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets.

C. Figdor, S. P. Sittig, J. Tel, 2013, Blood.

6 Gene expression in the course of experimental allergic encephalomyelitis : Relevance of antioxidant enzymes

E. Ronken, C. Dijkstra, C., 2012 .

Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression.

H. D. de Vries, P. Van Der Valk, J. van Horssen, 2008, Free radical biology & medicine.

Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination

W. Oyen, C. Figdor, A. Heerschap, 2013, Oncoimmunology.

Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells

W. Oyen, C. Figdor, A. Heerschap, 2013, Clinical Cancer Research.

Guidelines for mouse and human DC generation

M. Zenke, M. Lutz, S. Naik, 2022, European journal of immunology.

C. Figdor, E. Adang, J. Bonenkamp, 2018, Clinical and Translational Oncology.

NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions.

L. Bö, H. D. de Vries, F. L. van Muiswinkel, 2006, Free radical biology & medicine.

Antigen Cross-Presentation and Robust Type Plasmacytoid Dendritic Cells Triggers Targeting Uptake Receptors on Human

C. Figdor, S. P. Sittig, J. Tel, 2013 .

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

W. Gerritsen, K. Bol, I. D. de Vries, 2018, Front. Immunol..

Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3‐dioxygenase 1 with functional effects on T cell priming

C. Figdor, M. Verbeek, S. P. Sittig, 2021, European journal of immunology.

Dendritic Cell–Based Immunotherapy: State of the Art and Beyond

C. Figdor, W. Gerritsen, K. Bol, 2016, Clinical Cancer Research.

Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome

R. Kuiper, M. Jongmans, N. Hoogerbrugge, 2021, Cancers.

Development of an RNA-based kit for easy generation of TCR-engineered lymphocytes to control T-cell assay performance.

Cedrik M Britten, Marij J P Welters, Ugur Sahin, 2018, Journal of immunological methods.

Opportunities for immunotherapy in microsatellite instable colorectal cancer

C. Figdor, M. Ligtenberg, N. Hoogerbrugge, 2016, Cancer Immunology, Immunotherapy.

8 Enhanced antioxidant enzyme expression in inflammatory multiple sclerosis lesions

L. Bö, H. D. Vries, C. Dijkstra, 2012 .

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.

C. Figdor, C. Punt, J. Kaanders, 2011, The Journal of clinical investigation.

Recurrent candidiasis and early-onset gastric cancer in a patient with a genetically defined partial MYD88 defect

Trees Jansen, L. Jacobs, M. Netea, 2015, Familial Cancer.

Reactive oxygen species alter brain endothelial tight junction dynamics via RhoA, PI3 kinase, and PKB signaling

J. Piontek, I. Blasig, S. Gringhuis, 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer

I. D. de Vries, Georgina Flórez-Grau, G. Schreibelt, 2021, Frontiers in Immunology.

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer

J. Witjes, C. Figdor, J. Barentsz, 2019, Journal of Immunotherapy for Cancer.

PTEN Hamartoma Tumor Syndrome and Immune Dysregulation123

M. Netea, M. Ligtenberg, R. Netea-Maier, 2018, Translational oncology.

PTEN Hamartoma Tumor Syndrome and Immune Dysregulation123

M. Netea, M. Ligtenberg, R. Netea-Maier, 2018, Translational oncology.

Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination

C. Figdor, C. Punt, J. D. de Wilt, 2016, Oncoimmunology.

Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy

J. Tel, I. Schreurs, G. Schreibelt, 2014, Expert review of clinical immunology.

Dendritic Cell-Based Cancer Vaccines

C. Figdor, K. Bol, I. J. Vries, 2014 .

Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts

C. Figdor, K. Bol, I. J. Vries, 2013 .

Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy

C. Figdor, G. Adema, J. Tel, 2010, Cancer Immunology, Immunotherapy.

Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

C. Figdor, C. Punt, P. Coulie, 2010, Cancer Immunology, Immunotherapy.

In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients.

W. Oyen, C. Figdor, C. Punt, 2009, Cancer research.

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration

C. Figdor, C. Punt, G. Adema, 2008, Cancer Immunology, Immunotherapy.

Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.

M. Jongmans, N. Hoogerbrugge, I. D. de Vries, 2017, Cancer letters.

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination

C. Figdor, J. Haanen, R. Koornstra, 2016, Oncoimmunology.

Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients

I. Joosten, W. Gerritsen, M. D. de Jonge, 2017, Scientific Reports.

Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients.

W. Oyen, C. Figdor, C. Punt, 2013, Cancer research.

Clinical Studies Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Speci fi c T-Cell Responses in Melanoma Patients

W. Oyen, C. Figdor, C. Punt, 2013 .

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination

J. Haanen, J. D. de Groot, R. Koornstra, 2020, Oncoimmunology.

Skin-test infiltrating lymphocytes early predict clinical outcome of dendritic cell-based vaccination in metastatic melanoma.

C. Figdor, C. Punt, G. Adema, 2012, Cancer research.

of dendritic cell based vaccination in metastatic melanoma Skin-test infiltrating lymphocytes early predict clinical outcome

K. Bol, W. Lesterhuis, G. Schreibelt, 2012 .

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells

G. Coukos, B. Neyns, I. Melero, 2019, Journal of Immunotherapy for Cancer.

Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients

C. Figdor, C. Punt, G. Adema, 2012, Clinical Cancer Research.

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial

C. Figdor, C. Punt, R. Koornstra, 2020, Cancer Immunology, Immunotherapy.

Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients.

C. Figdor, C. Punt, G. Adema, 2010, Anticancer research.

Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion

C. Figdor, S. P. Sittig, J. Tel, 2013, The Journal of Immunology.

Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation

S. P. Sittig, I. D. de Vries, G. Schreibelt, 2015, Biomedicines.

Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets

C. Figdor, F. Wimmers, I. D. de Vries, 2014, Front. Immunol..

Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination.

A. Croockewit, D. Schadendorf, C. Figdor, 2013, Cancer research.

C. Figdor, C. Punt, R. Koornstra, 2016, Journal of immunotherapy.

Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function

M. Huynen, Shivakumar Keerthikumar, C. Figdor, 2016, Cell reports.

Long overall survival after dendritic cell vaccination in metastatic uveal melanoma patients.

C. Figdor, J. Keunen, C. Punt, 2014, American journal of ophthalmology.

Cancer Therapy : Clinical Targeting of 111 In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells

W. Oyen, C. Figdor, A. Heerschap, 2013 .

Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG

L. Massuger, R. Torensma, I. D. de Vries, 2018, Front. Immunol..

Radical changes in multiple sclerosis pathogenesis.

H. D. de Vries, J. van Horssen, G. Schreibelt, 2011, Biochimica et biophysica acta.

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy

C. Figdor, C. Punt, W. Gerritsen, 2013, Oncoimmunology.

What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.

Jarno Hoekman, Marcel H N Hoefnagel, Gerty Schreibelt, 2020, Cytotherapy.

J. Witjes, C. Figdor, P. Ottevanger, 2020, Frontiers in Oncology.

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients

C. Figdor, C. Punt, K. Bol, 2015, Journal of Immunotherapy for Cancer.

CD1 and major histocompatibility complex II molecules follow a different course during dendritic cell maturation.

Gerty Schreibelt, Peter J Peters, Michael B Brenner, 2003, Molecular biology of the cell.

Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study.

K. Nicolay, H. D. de Vries, E. Blezer, 2004, Brain : a journal of neurology.

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients

C. Figdor, J. Keunen, C. Punt, 2015, Journal of Immunotherapy for Cancer.

1105PVEMURAFENIB FOR BRAF V600 MUTATED ADVANCED MELANOMA: RESULTS OF TREATMENT BEYOND PROGRESSION.

Y. S. Kim, Su Jin Lee, J. Utikal, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function

M. Huynen, Shivakumar Keerthikumar, C. Figdor, 2016, Cell reports.

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets

C. Figdor, S. P. Sittig, J. Tel, 2016, Mediators of inflammation.

Radical changes in multiple sclerosis pathogenesis.

H. D. de Vries, J. van Horssen, G. Schreibelt, 2011, Biochimica et biophysica acta.

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.

C. Figdor, C. Punt, J. Kaanders, 2011, The Journal of clinical investigation.

Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells

W. Oyen, C. Figdor, A. Heerschap, 2013, Clinical Cancer Research.

Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration

C. Figdor, C. Punt, G. Adema, 2008, Cancer Immunology, Immunotherapy.

Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma.

N. Naus, A. de Klein, W. Gerritsen, 2016, Ophthalmology.

Influence of microbiota-associated metabolic reprogramming on clinical outcome in patients with melanoma from the randomized adjuvant dendritic cell-based MIND-DC trial

F. Asnicar, F. Armanini, L. Zitvogel, 2024, Nature Communications.

Adjuvant dendritic cell therapy in stage IIIB/C melanoma: the MIND-DC randomized phase III trial

Inge M. N. Wortel, J. Bonenkamp, W. Gerritsen, 2024, Nature communications.

Dendritic cell vaccination combined with carboplatin/paclitaxel for metastatic endometrial cancer patients: results of a phase I/II trial

B. Koeneman, G. Schreibelt, H. Westdorp, 2024, Frontiers in immunology.

1078MO MIND-DC: A randomized phase III trial to assess the efficacy of adjuvant dendritic cell vaccination in comparison to placebo in stage IIIB and IIIC melanoma patients

C. Figdor, A. Veldt, W. Gerritsen, 2020 .

Design of TOLERANT: phase I/II safety assessment of intranodal administration of HSP70/mB29a self-peptide antigen-loaded autologous tolerogenic dendritic cells in patients with rheumatoid arthritis.

F. Broere, A. J. Stoppelenburg, B. Koeneman, 2024, BMJ open.